All In Biotech

Drug Trial Radar · NCT06534437

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination With Glofitamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 178 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

178

Planned (sponsor's estimate)

Start

Dec 5, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Ryvu Therapeutics SAIndustry
Sponsor type
Industry
Collaborators
Menarini Group
First posted
Aug 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time: * Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma * Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma Group 1 patients will be treated for a maximum of 12 cycles. One cycle is 21 days. Group 2 with be treated until the disease progresses, therefore treatment duration is dependent on the number of treatment cycles a participant receives prior to progression.

Conditions

  • Non-Hodgkin Lymphoma, B-cell

Interventions

  • MEN1703Drug

    MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).

  • GlofitamabDrug

    Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence and severity of adverse events (AE)Time frame: 12 months
  2. Part 2 and Part 3: Complete response (CR) (group 1)Time frame: 12 months
  3. Part 2 and Part 3: Overall response rate (group 2)Time frame: 12 months

Locations

35 sites in 4 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier Le Mans

    Le Mans, France · Recruiting

  • CHU de Lille - Hôpital Claude Huriez

    Lille, France · Recruiting

  • CHU de Limoges - CHU Dupuytren

    Limoges, France · Recruiting

  • Hospices Civils De Lyon - Hôpital Lyon Sud

    Lyon, France · Recruiting

  • CHU Montpellier - Hôpital Saint Eloi

    Montpellier, France · Recruiting

  • APHP - Hôpital Pitié-Salpêtrière

    Paris, France · Recruiting

  • CHU de Bordeaux - Hôpital Haut-Lévêque

    Pessac, France · Recruiting

  • Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej

    Biała Podlaska, Poland · Terminated

  • IN-VIVO Bydgoszcz Sp. z o.o.

    Bydgoszcz, Poland · Recruiting

  • Klinika Hematologii I Transplantologii Uck

    Gdansk, Poland · Not yet recruiting

  • Szpitale Pomorskie Sp. z o.o.

    Gdynia, Poland · Recruiting

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy

    Gliwice, Poland · Recruiting

  • Pratia Hematologia Sp. z o.o.

    Katowice, Poland · Terminated

  • Pratia MCM Kraków

    Krakow, Poland · Recruiting

  • SP ZOZ Szpital Uniwersytecki w Krakowie

    Krakow, Poland · Recruiting

  • Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie

    Olsztyn, Poland · Recruiting

  • Aidport Sp. z o.o.

    Skórzewo, Poland · Recruiting

  • Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu

    Torun, Poland · Recruiting

  • Lux Med Onkologia Sp. z o.o.

    Warsaw, Poland · Terminated

  • Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy

    Warsaw, Poland · Terminated

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain · Recruiting

  • Clinica Universidad De Navarra

    Madrid, Spain · Recruiting

  • MD Anderson Cancer Center

    Madrid, Spain · Recruiting

  • Hospital Universitario Puerta de Hierro Majadahonda

    Madrid, Spain · Recruiting

  • Hospital Clínico Uni versitario Virgen de la Arrixaca

    Murcia, Spain · Not yet recruiting

  • Clinica Universidad De Navarra

    Pamplona, Spain · Recruiting

  • Hospital Universitario De Navarra

    Pamplona, Spain · Recruiting

  • Hospital Universitario De Salamanca

    Salamanca, Spain · Recruiting

  • Hospital Universitario Virgen De La Macarena

    Seville, Spain · Recruiting

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain · Recruiting

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Plymouth Hospitals NHS Trust

    Plymouth, United Kingdom · Recruiting

  • The Royal Marsden Hospital

    Sutton, United Kingdom · Recruiting

  • St George's Hospital

    Tooting, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.